News for SK Biopharmaceuticals Co., Ltd. (326030.KS)

Data Exemplify Overall Capabilities and Advances in Company’s Pipeline...

KING OF PRUSSIA, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals,...

SK Life Science, Inc. uses modern cloud solution to accelerate validation processes for increased inspection readiness PLEASANTON, Calif., Jan. 11, 2024 /PRNewswire/ -- Veeva Systems today...

Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million,...

Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation...

New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor...

/PRNewswire/ -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central...

These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical’s targeted protein...

/PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board (SAB), comprising of five prominent...

/PRNewswire/ -- SK Biopharmaceuticals announced that it has unveiled its new strategy that will enable the company take a leap toward becoming a global "big...